{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:31Z","timestamp":1788966031825,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Gastroenterological Association of Thailand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the COVID-19 pandemic, healthcare facility supply and access are limited. There was an announcement promoting <jats:italic>Andrographis paniculata<\/jats:italic> (ADG) use for treatment of mild COVID-19 patients in Thailand, but misconception of taking for prevention might occur. Moreover, the effect of ADG on liver function test (LFT) has not been established. To study the ADG use and effect on LFT in patients with gastrointestinal (GI) problems, conducted a cross-sectional study including GI patients who voluntarily filled the ADG questionnaire in Aug\u2013Sep 2021. LFT data at that visit and at the prior visit (if available) were obtained. The changes in LFT within the same person were analyzed and compared between patients with and without ADG consumption. During the study period,\u00a0a total of 810 patients completed the survey, 168 patients (20.7%) took ADG within the past month. LFT data were available in 485 (59.9%) patients, the median alanine aminotransferase (ALT)\u00a0 change compared with the prior visit was higher in the\u00a0ADG vs control group (+\u20092 vs 0, p\u2009=\u20090.029), and 44.5% had increased ALT (&gt;\u20093 U\/L) vs 32.2% in the\u00a0ADG and control group, respectively (p\u2009=\u20090.018). Factors independently associated with an increased ALT, from a multivariable logistic regression, were ADG exposure (adjusted OR 1.62, p\u2009=\u20090.042), and patients with NAFLD who gained weight (adjusted OR 2.37, p\u2009=\u20090.046). In conclusion, one-fifth of GI patients recently took ADG, even it is not recommended for COVID-19 prevention. Those who took ADG are more likely to experience an increased ALT than who did not. The potential risk of ADG consumption on liver function should be further assessed.<\/jats:p>","DOI":"10.1038\/s41598-022-23189-7","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T10:15:09Z","timestamp":1667038509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross sectional study"],"prefix":"10.1038","volume":"12","author":[{"given":"Apichat","family":"Kaewdech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwanon","family":"Nawalerspanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraphon","family":"Assawasuwannakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naichaya","family":"Chamroonkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawangpong","family":"Jandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimsiri","family":"Sripongpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"issue":"5","key":"23189_CR1","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/nu13051550","volume":"13","author":"D A\u011fag\u00fcnd\u00fcz","year":"2021","unstructured":"A\u011fag\u00fcnd\u00fcz, D., \u00c7elik, M., \u00c7\u0131tarDaz\u0131ro\u011flu, M. & Capasso, R. Emergent drug and nutrition interactions in COVID-19: A comprehensive narrative review. Nutrients 13(5), 1550 (2021).","journal-title":"Nutrients"},{"key":"23189_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/7170736","volume":"2021","author":"TE Tallei","year":"2021","unstructured":"Tallei, T. E. et al. A comprehensive review of the potential use of green tea polyphenols in the management of COVID-19. Evid.-Based Complement. Altern. Med. 2021, 1\u201313 (2021).","journal-title":"Evid.-Based Complement. Altern. Med."},{"issue":"sup1","key":"23189_CR3","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1080\/10408398.2018.1501657","volume":"59","author":"Y Dai","year":"2019","unstructured":"Dai, Y. et al. Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide. Crit. Rev. Food Sci. Nutr. 59(sup1), S17\u2013S29 (2019).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"3","key":"23189_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4236\/cm.2012.33022","volume":"3","author":"WW Chao","year":"2012","unstructured":"Chao, W. W. & Lin, B. F. Hepatoprotective diterpenoids isolated from Andrographis paniculata. Chin. Med. 3(3), 136\u2013143 (2012).","journal-title":"Chin. Med."},{"issue":"11","key":"23189_CR5","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/ptr.5193","volume":"28","author":"LS Chua","year":"2014","unstructured":"Chua, L. S. Review on liver inflammation and antiinflammatory activity of Andrographis paniculata for hepatoprotection. Phytother. Res. 28(11), 1589\u20131598 (2014).","journal-title":"Phytother. Res."},{"issue":"2\u20133","key":"23189_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jep.2004.03.004","volume":"92","author":"RA Kumar","year":"2004","unstructured":"Kumar, R. A., Sridevi, K., Kumar, N. V., Nanduri, S. & Rajagopal, S. Anticancer and immunostimulatory compounds from Andrographis paniculata. J. Ethnopharmacol. 92(2\u20133), 291\u2013295 (2004).","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"23189_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1021\/acs.jnatprod.0c01324","volume":"84","author":"K Sa-Ngiamsuntorn","year":"2021","unstructured":"Sa-Ngiamsuntorn, K. et al. Anti-SARS-CoV-2 activity of andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives. J. Nat. Prod. 84(4), 1261\u20131270 (2021).","journal-title":"J. Nat. Prod."},{"issue":"9","key":"23189_CR8","first-page":"3092","volume":"39","author":"SK Enmozhi","year":"2021","unstructured":"Enmozhi, S. K., Raja, K., Sebastine, I. & Joseph, J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach. J. Biomol. Struct. Dyn. 39(9), 3092\u20133098 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"23189_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bbrc.2020.08.086","volume":"533","author":"TH Shi","year":"2020","unstructured":"Shi, T. H. et al. Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage. Biochem. Biophys. Res. Commun. 533(3), 467\u2013473 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"23189_CR10","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1002\/ptr.7141","volume":"35","author":"XY Zhang","year":"2021","unstructured":"Zhang, X. Y. et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial. Phytother. Res. 35(8), 4401\u20134410 (2021).","journal-title":"Phytother. Res."},{"issue":"4","key":"23189_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/japtr.JAPTR_84_20","volume":"11","author":"M Ervina","year":"2020","unstructured":"Ervina, M., Fadhil Pratama, M. R., Poerwono, H. & Siswodihardjo, S. The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness. J. Adv. Pharm. Technol. Res. 11(4), 157\u2013162 (2020).","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"2","key":"23189_CR12","first-page":"333","volume":"11","author":"P Pokhagul","year":"2019","unstructured":"Pokhagul, P. & Kulsomboon, W. Signal detection of blood glucose lowering drugs and herbal medicines in the Thai databases on adverse drug events (Thai Vigibase). Thai J. Pharm. Pract. 11(2), 333\u2013341 (2019).","journal-title":"Thai J. Pharm. Pract."},{"issue":"1","key":"23189_CR13","first-page":"229","volume":"19","author":"A Benjaponpithak","year":"2021","unstructured":"Benjaponpithak, A., Visithanon, K., Sawaengtham, T., Thaneerat, T. & Wanaratna, K. Short communication on use of andrographis herb (FA THALAI CHON) for the treatment of COVID-19 patients. J. Thai Tradit. Altern. Med. 19(1), 229\u2013233 (2021).","journal-title":"J. Thai Tradit. Altern. Med."},{"issue":"1","key":"23189_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/1472-6882-14-515","volume":"14","author":"W Suwankesawong","year":"2014","unstructured":"Suwankesawong, W., Saokaew, S., Permsuwan, U. & Chaiyakunapruk, N. Characterization of hypersensitivity reactions reported among Andrographis paniculata users in Thailand using Health Product Vigilance Center (HPVC) database. BMC Complement. Altern. Med. 14(1), 515 (2014).","journal-title":"BMC Complement. Altern. Med."},{"issue":"1","key":"23189_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.yrtph.2014.06.007","volume":"70","author":"S Wechwithan","year":"2014","unstructured":"Wechwithan, S. et al. Signal detection for Thai traditional medicine: Examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk. Regul. Toxicol. Pharmacol. 70(1), 407\u2013412 (2014).","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"5","key":"23189_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/1099-1573(200008)14:5<333::AID-PTR584>3.0.CO;2-D","volume":"14","author":"C Calabrese","year":"2000","unstructured":"Calabrese, C. et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother. Res. 14(5), 333\u2013338 (2000).","journal-title":"Phytother. Res."},{"issue":"4","key":"23189_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/17425255.2017.1252749","volume":"13","author":"R Teschke","year":"2017","unstructured":"Teschke, R. & Danan, G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?. Expert Opin. Drug Metab. Toxicol. 13(4), 425\u2013438 (2017).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"13","key":"23189_CR18","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.cgh.2018.12.013","volume":"17","author":"C Lammert","year":"2019","unstructured":"Lammert, C., Imler, T., Teal, E. & Chalasani, N. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin. Gastroenterol. Hepatol. 17(13), 2814\u20132815 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"23189_CR19","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver. Clinical Practice Guideline Panel: Chair: Panel members, EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol. 70(6), 1222\u20131261 (2019).","journal-title":"J. Hepatol."},{"issue":"4","key":"23189_CR20","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4), 1560\u20131599 (2018).","journal-title":"Hepatology"},{"key":"23189_CR21","unstructured":"Statistical Methods for Rates and Proportions, 3rd ed | Wiley. Wiley.com. (Accessed 5 Feb 2022) https:\/\/www.wiley.com\/en-in\/Statistical+Methods+for+Rates+and+Proportions%2C+3rd+Edition-p-9780471526292."},{"key":"23189_CR22","first-page":"160","volume":"68","author":"C Ngamjarus","year":"2016","unstructured":"Ngamjarus, C., Chongsuvivatwong, V. & McNeil, E. n4Studies: Sample size calculation for an epidemiological study on a smart device. Siriraj Med. J. 68, 160\u2013170 (2016).","journal-title":"Siriraj Med. J."},{"key":"23189_CR23","doi-asserted-by":"crossref","unstructured":"Charan, J. et al. Use of complementary and alternative medicine (CAM) and home remedies by COVID-19 patients: A telephonic survey. Indian J. Clin. Biochem. 36(1), 108\u2013111 (2020).","DOI":"10.1007\/s12291-020-00931-4"},{"issue":"1","key":"23189_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13002-021-00449-w","volume":"17","author":"D Khadka","year":"2021","unstructured":"Khadka, D. et al. The use of medicinal plants to prevent COVID-19 in Nepal. J. Ethnobiol. Ethnomed. 17(1), 26 (2021).","journal-title":"J. Ethnobiol. Ethnomed."},{"issue":"12","key":"23189_CR25","doi-asserted-by":"publisher","first-page":"e0243706","DOI":"10.1371\/journal.pone.0243706","volume":"15","author":"I Ahmed","year":"2020","unstructured":"Ahmed, I. et al. Behavioral preventive measures and the use of medicines and herbal products among the public in response to Covid-19 in Bangladesh: A cross-sectional study. PLoS ONE 15(12), e0243706 (2020).","journal-title":"PLoS ONE"},{"issue":"7","key":"23189_CR26","doi-asserted-by":"publisher","first-page":"e0253890","DOI":"10.1371\/journal.pone.0253890","volume":"16","author":"CS Lam","year":"2021","unstructured":"Lam, C. S., Koon, H. K., Chung, V. C. H. & Cheung, Y. T. A public survey of traditional, complementary and integrative medicine use during the COVID-19 outbreak in Hong Kong. PLoS ONE 16(7), e0253890 (2021).","journal-title":"PLoS ONE"},{"issue":"9","key":"23189_CR27","doi-asserted-by":"publisher","first-page":"e0257165","DOI":"10.1371\/journal.pone.0257165","volume":"16","author":"M Villena-Tejada","year":"2021","unstructured":"Villena-Tejada, M. et al. Use of medicinal plants for COVID-19 prevention and respiratory symptom treatment during the pandemic in Cusco, Peru: A cross-sectional survey. PLoS ONE 16(9), e0257165 (2021).","journal-title":"PLoS ONE"},{"key":"23189_CR28","doi-asserted-by":"publisher","first-page":"846740","DOI":"10.1155\/2013\/846740","volume":"2013","author":"T Jayakumar","year":"2013","unstructured":"Jayakumar, T., Hsieh, C. Y., Lee, J. J. & Sheu, J. R. Experimental and clinical pharmacology of Andrographis paniculata and its major bioactive phytoconstituent andrographolide. Evid. Based Complement. Altern. Med. 2013, 846740 (2013).","journal-title":"Evid. Based Complement. Altern. Med."},{"issue":"6","key":"23189_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00580-012-1539-x","volume":"22","author":"C Bothiraja","year":"2012","unstructured":"Bothiraja, C., Pawar, A., Shende, V. & Joshi, P. Acute and subacute toxicity study of andrographolide bioactive in rodents: Evidence for the medicinal use as an alternative medicine. Comp. Clin. Pathol. 22(6), 1123\u20131128 (2012).","journal-title":"Comp. Clin. Pathol."},{"issue":"2","key":"23189_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3350\/cmh.2019.1003","volume":"26","author":"EXS Low","year":"2019","unstructured":"Low, E. X. S., Zheng, Q., Chan, E. & Lim, S. G. Drug induced liver injury: East versus West\u2014A systematic review and meta-analysis. Clin. Mol. Hepatol. 26(2), 142\u2013154 (2019).","journal-title":"Clin. Mol. Hepatol."},{"issue":"9","key":"23189_CR31","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.cgh.2017.12.051","volume":"16","author":"I Medina-Caliz","year":"2018","unstructured":"Medina-Caliz, I. et al. Herbal and dietary supplement-induced liver injuries in the Spanish DILI Registry. Clin. Gastroenterol. Hepatol. 16(9), 1495\u20131502 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"23189_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.12109","volume":"37","author":"C Bunchorntavakul","year":"2013","unstructured":"Bunchorntavakul, C. & Reddy, K. R. Review article: Herbal and dietary supplement hepatotoxicity. Aliment. Pharmacol. Ther. 37(1), 3\u201317 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"9","key":"23189_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41574-020-0387-z","volume":"16","author":"C Clemmensen","year":"2020","unstructured":"Clemmensen, C., Petersen, M. B. & S\u00f8rensen, T. I. A. Will the COVID-19 pandemic worsen the obesity epidemic?. Nat. Rev. Endocrinol. 16(9), 469\u2013470 (2020).","journal-title":"Nat. Rev. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23189-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T10:24:09Z","timestamp":1667039049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23189-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23189"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23189-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18213"}}